NO984939L - Azetidinon-derivater for behandling av atherosklerose - Google Patents

Azetidinon-derivater for behandling av atherosklerose

Info

Publication number
NO984939L
NO984939L NO984939A NO984939A NO984939L NO 984939 L NO984939 L NO 984939L NO 984939 A NO984939 A NO 984939A NO 984939 A NO984939 A NO 984939A NO 984939 L NO984939 L NO 984939L
Authority
NO
Norway
Prior art keywords
hydrogen
atherosclerosis
treatment
alkyl
pharmaceutically acceptable
Prior art date
Application number
NO984939A
Other languages
English (en)
Norwegian (no)
Other versions
NO984939D0 (no
Inventor
Colin Andrew Leach
Deidre Mary Bernadette Hickey
Robert John Ife
Colin Theobald
Dashyant Dhanak
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608646.7A external-priority patent/GB9608646D0/en
Priority claimed from GBGB9623756.5A external-priority patent/GB9623756D0/en
Priority claimed from GBGB9625121.0A external-priority patent/GB9625121D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO984939D0 publication Critical patent/NO984939D0/no
Publication of NO984939L publication Critical patent/NO984939L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO984939A 1996-04-26 1998-10-23 Azetidinon-derivater for behandling av atherosklerose NO984939L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9608646.7A GB9608646D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9623756.5A GB9623756D0 (en) 1996-11-15 1996-11-15 Novel compounds
GBGB9625121.0A GB9625121D0 (en) 1996-12-03 1996-12-03 Novel compounds
PCT/EP1997/001898 WO1997041098A1 (fr) 1996-04-26 1997-04-15 Derives azetidinones destines au traitement de l'atherosclerose

Publications (2)

Publication Number Publication Date
NO984939D0 NO984939D0 (no) 1998-10-23
NO984939L true NO984939L (no) 1998-12-23

Family

ID=27268259

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984939A NO984939L (no) 1996-04-26 1998-10-23 Azetidinon-derivater for behandling av atherosklerose

Country Status (17)

Country Link
EP (1) EP0915843A1 (fr)
JP (1) JP2000509049A (fr)
AR (1) AR006833A1 (fr)
AU (1) AU2698697A (fr)
BR (1) BR9709196A (fr)
CA (1) CA2252696A1 (fr)
CZ (1) CZ341098A3 (fr)
HU (1) HUP9901359A3 (fr)
ID (1) ID16660A (fr)
IL (1) IL126696A0 (fr)
MA (1) MA26426A1 (fr)
NO (1) NO984939L (fr)
NZ (1) NZ332476A (fr)
PE (1) PE64398A1 (fr)
PL (1) PL329530A1 (fr)
TR (1) TR199802160T2 (fr)
WO (1) WO1997041098A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1263740T3 (da) 2000-02-16 2006-11-13 Smithkline Beecham Plc Pyrimidin-4-on-derivat som LDL-PLA2-inhibitor
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
IL157552A0 (en) 2001-03-28 2004-03-28 Schering Corp Enantioselective synthesis of azetidinone intermediate compounds
DE60216275T2 (de) * 2001-05-25 2007-06-21 Schering Corp. Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1429756B1 (fr) 2001-09-21 2006-11-22 Schering Corporation Methodes et combinaisons therapeutiques utiles pour le traitement du xanthome effectue avec des inhibiteurs d'absorption du sterol
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN101687009A (zh) 2007-05-11 2010-03-31 宾夕法尼亚大学理事会 治疗皮肤溃疡的方法
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
KR101730290B1 (ko) 2007-05-11 2017-04-25 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
KR101861883B1 (ko) 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
ES2847883T3 (es) 2010-12-17 2021-08-04 Glaxo Group Ltd Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
CN103619831B (zh) 2011-06-27 2016-05-04 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
AR087309A1 (es) 2011-07-27 2014-03-12 Glaxo Group Ltd Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis
CA2842965A1 (fr) 2011-07-27 2013-01-31 Glaxo Group Limited Composes 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1h)-one et utilisation en tant qu'inhibiteurs de lp-pla2
MX2015009633A (es) 2013-01-25 2015-11-30 Glaxosmithkline Ip Dev Ltd Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona.
US9296755B2 (en) 2013-01-25 2016-03-29 Glaxosmithkline Intellectual Property Development Limited 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds and their therapeutic applications
EP2948456A4 (fr) 2013-01-25 2016-09-14 Glaxosmithkline Ip Dev Ltd Composés de pyrimidone bicycliques utilisés en tant qu'inhibiteurs de lp-pla2
WO2016012917A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
WO2016012916A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
EP4056571A4 (fr) 2019-11-09 2024-01-24 Shanghai Simr Biotechnology Co., Ltd. Dérivé de dihydroimidazopyrimidone tricyclique, son procédé de préparation, composition pharmaceutique et son utilisation
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
WO2025015951A1 (fr) 2023-07-17 2025-01-23 上海枢境生物科技有限公司 Dérivé de bicyclo[5,6]imidazole pyrimidone, son procédé de préparation et son utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL89835A0 (en) * 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1993000332A1 (fr) * 1991-06-25 1993-01-07 Merck & Co., Inc. Azetidinones substituees utilisees comme agents antiinflammatoires et antidegeneratifs
TW223059B (fr) * 1991-07-23 1994-05-01 Schering Corp
CA2108584C (fr) * 1992-10-27 1998-11-24 James B. Doherty Utilisation d'azetidinones substituees comme anti-inflammatoires et agents anti-degeneratifs
AU5802894A (en) * 1992-12-17 1994-07-04 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
EP0658205B1 (fr) * 1993-06-25 2000-03-15 Smithkline Beecham Plc Phospholipase a2 associee a une lipoproteine, inhibiteurs de cette phospholipase et son utilisation a des fins diagnostiques et therapeutiques
ATE315655T1 (de) * 1993-10-06 2006-02-15 Icos Corp Acethylhydrolase des plättchen aktivierenden faktors
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
HUT77089A (hu) * 1994-12-22 1998-03-02 Smithkline Beecham Plc. Atherosclerosis kezelésére alkalmas szubsztituált 2-oxo-azetidinek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
AU5014496A (en) * 1995-03-23 1996-10-08 Japan Tobacco Inc. Diphenylmethyl-azetidinone compounds and elastase inhibitor
CN1197452A (zh) * 1995-07-01 1998-10-28 史密丝克莱恩比彻姆有限公司 用于治疗动脉粥样硬化的氮杂环丁烷酮衍生物
JP2000505063A (ja) * 1995-12-08 2000-04-25 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン化合物

Also Published As

Publication number Publication date
BR9709196A (pt) 1999-05-25
WO1997041098A1 (fr) 1997-11-06
PE64398A1 (es) 1999-01-06
AR006833A1 (es) 1999-09-29
TR199802160T2 (xx) 1999-04-21
AU2698697A (en) 1997-11-19
CZ341098A3 (cs) 1999-03-17
CA2252696A1 (fr) 1997-11-06
HUP9901359A3 (en) 2000-03-28
PL329530A1 (en) 1999-03-29
IL126696A0 (en) 1999-08-17
JP2000509049A (ja) 2000-07-18
HUP9901359A2 (hu) 1999-08-30
NO984939D0 (no) 1998-10-23
NZ332476A (en) 2000-06-23
MA26426A1 (fr) 2004-12-20
ID16660A (id) 1997-10-30
EP0915843A1 (fr) 1999-05-19

Similar Documents

Publication Publication Date Title
TR199802160T2 (xx) Ateroskleroz tedavisi i�in azetidinon t�revleri.
AP9701007A0 (en) Substituted azetidin-2-ones for treatment of atherosclerosis.
DE69607650D1 (de) 2,3,5-trimethyl-hydroxyanilid-derivative, ihre herstellung und ihre theraoeutische verwendung
NO992821L (no) Ketobenzamider som calpain-inhibitorer
NO960371L (no) Piperazinderivater som ter
NO982913L (no) Kinolin- og kinazolinforbindelser nyttige i terapi
NO20024521L (no) Heterocyklisk sidekjede-inneholdende metalloproteaseinhibitorer
WO2000071511A3 (fr) INHIBITEURS DU FACTEUR Xa
PL354063A1 (en) Cell adhesion inhibitors
IL155155A0 (en) BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
NO976158L (no) Azetidinon-derivater for behandling av atherosklerose
TR200002971T2 (tr) İkameli pirolidin hidroksamat metaloproteaz inhibitörleri
NO911121D0 (no) Fremgangsmaate for fremstilling av nye skvalen-synetase-inhibitorer.
NO984740L (no) Isatinderivater som acetylcholinesteraseinhibitorer og analgetiske midler
WO2000051993A3 (fr) Inhibiteurs de metalloproteases dihetero-substitues
ID26622A (id) Senyawa-senyawa pengganti 2-benzylamino-2-phenyl-acetamide
NZ332834A (en) Glycosaminoglycan-related carbohydrate derivatives ( 5 saccharide groups ) having 4 to 6 sulphate groups
NO951147L (no) Substituerte heterocykliske karboksylsyreamidestere, deres fremstilling og deres anvendelse som legemiddel
ATE233741T1 (de) Antivirale 2,4-pyrimidindion-derivate und verfahren zu ihrer herstellung
PL317349A1 (en) Organic compounds
NO983525L (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
DE69528978D1 (de) Lactamverbindungen als Inhibitoren der Cholesterin-Esterase
AP2004003084A0 (en) 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
DK0660822T3 (da) Cykliske benzylamino-, benzylamido- og benzylimidoderivater som antipsykotiske midler
NO983283L (no) Hydrokamsyre-baserte Kollagenase-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application